Hepatitis B in Pregnancy: Specific Issues and Considerations
Vincent Ho* and William Ho
University of Western Sydney, Sydney, NSW, Australia
- *Corresponding Author:
- Vincent Ho
MBBS BSc (Med) MMed FRACP FACP
University of Western Sydney
Sydney, NSW, Australia
E-mail: [email protected]
Received Date: April 21, 2012; Accepted Date: June 11, 2012; Published Date: June 13, 2012
Citation: Ho V, Ho W (2012) Hepatitis B in Pregnancy: Specific Issues and Considerations. J Antivir Antiretrovir 4: 051-059. doi: 10.4172/jaa.1000046
Copyright: © 2012 Ho V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Chronic hepatitis B affects over 350 million people worldwide. Vertical transmission is known to be the leading cause of infection and perinatal infection is associated with a very high rate of chronicity (up to 90%). Up to 40% of chronically infected individuals will die prematurely from complications such as acute liver failure, cirrhosis and hepatocellular cancer. Addressing perinatal transmission through the use of immunoprophylaxis can help contain the spread of HBV. Pregnant mothers with chronic hepatitis B have unique challenges and require specialised management during and after pregnancy.
This review will look at the screening of pregnant women for hepatitis B, passive and active immunoprophylaxis, mechanisms of perinatal viral transmission and therapeutic considerations in pregnancy including possible teratogenicity and efficacy of medication. Other issues such as the mode of delivery and breastfeeding will be covered.